Anne Trinh1, Irene Chan2, Maria Alexiadis3, Medina Pell3, Beena Kumar4, Peter J Fuller1. 1. Department of Endocrinology, Monash Medical Centre, Clayton, Victoria, Australia; Hudson Institute of Medical Research, Clayton, Victoria, Australia. 2. Department of Endocrinology, Monash Medical Centre, Clayton, Victoria, Australia. 3. Hudson Institute of Medical Research, Clayton, Victoria, Australia. 4. Department of Anatomical Pathology, Monash Medical Centre, Clayton, Victoria, Australia.
Abstract
BACKGROUND: Cushing's syndrome is rare during pregnancy and more commonly due to adrenal pathology, in contrast to the non-pregnant population. Increased levels of cortisol-binding globulin and placental production of corticotropin-releasing hormone and adrenocorticotropic hormone complicate the diagnostic strategies usually employed. CASE: A 32-year-old G1P0 at 15/40 gestation presented with severe peripheral oedema and excessive weight gain. Examination revealed pitting oedema to the abdominal wall, wide violaceous striae, moon facies and acne. Cortisol excess was confirmed with elevated 24 h urinary free cortisol, raised midnight salivary cortisol and lack of diurnal variation. Adrenocorticotropic hormone ranged between 22 and 36 pg/ml (5-8 pmol/L). Fetal ultrasound confirmed a single live intrauterine gestation with an incidental finding of a maternal left adrenal mass. Magnetic resonance imaging confirmed an adrenal mass measuring 3.0 × 4.4 × 4.1 cm. She underwent a laparoscopic left adrenalectomy at 18 weeks' gestation without complication. Her postoperative cortisol level was undetectable. Hydrocortisone replacement was commenced with slow weaning as an outpatient. Histology was consistent with an adrenal adenoma. Immunohistochemistry revealed strong staining for the luteinising hormone/choriogonadotropin receptor, and expression of the luteinising hormone/choriogonadotropin receptor gene was in the range seen in normal ovary. DNA analysis revealed a mutation in GNAS encoding the Gα subunit in the cyclic adenosine monophosphate pathway. CONCLUSION: Cushing's syndrome may present in pregnancy as a result of βhCG acting on the luteinising hormone/choriogonadotropin receptor over-expression by the adenoma amplifying the aberrant cyclic adenosine monophosphate signaling implicated in the development of cortisol-secreting adenomas.
BACKGROUND:Cushing's syndrome is rare during pregnancy and more commonly due to adrenal pathology, in contrast to the non-pregnant population. Increased levels of cortisol-binding globulin and placental production of corticotropin-releasing hormone and adrenocorticotropic hormone complicate the diagnostic strategies usually employed. CASE: A 32-year-old G1P0 at 15/40 gestation presented with severe peripheral oedema and excessive weight gain. Examination revealed pitting oedema to the abdominal wall, wide violaceous striae, moon facies and acne. Cortisol excess was confirmed with elevated 24 h urinary free cortisol, raised midnight salivary cortisol and lack of diurnal variation. Adrenocorticotropic hormone ranged between 22 and 36 pg/ml (5-8 pmol/L). Fetal ultrasound confirmed a single live intrauterine gestation with an incidental finding of a maternal left adrenal mass. Magnetic resonance imaging confirmed an adrenal mass measuring 3.0 × 4.4 × 4.1 cm. She underwent a laparoscopic left adrenalectomy at 18 weeks' gestation without complication. Her postoperative cortisol level was undetectable. Hydrocortisone replacement was commenced with slow weaning as an outpatient. Histology was consistent with an adrenal adenoma. Immunohistochemistry revealed strong staining for the luteinising hormone/choriogonadotropin receptor, and expression of the luteinising hormone/choriogonadotropin receptor gene was in the range seen in normal ovary. DNA analysis revealed a mutation in GNAS encoding the Gα subunit in the cyclic adenosine monophosphate pathway. CONCLUSION:Cushing's syndrome may present in pregnancy as a result of βhCG acting on the luteinising hormone/choriogonadotropin receptor over-expression by the adenoma amplifying the aberrant cyclic adenosine monophosphate signaling implicated in the development of cortisol-secreting adenomas.
Authors: John R Lindsay; Jacqueline Jonklaas; Edward H Oldfield; Lynnette K Nieman Journal: J Clin Endocrinol Metab Date: 2005-02-10 Impact factor: 5.958
Authors: Felix Beuschlein; Martin Fassnacht; Guillaume Assié; Davide Calebiro; Constantine A Stratakis; Andrea Osswald; Cristina L Ronchi; Thomas Wieland; Silviu Sbiera; Fabio R Faucz; Katrin Schaak; Anett Schmittfull; Thomas Schwarzmayr; Olivia Barreau; Delphine Vezzosi; Marthe Rizk-Rabin; Ulrike Zabel; Eva Szarek; Paraskevi Salpea; Antonella Forlino; Annalisa Vetro; Orsetta Zuffardi; Caroline Kisker; Susanne Diener; Thomas Meitinger; Martin J Lohse; Martin Reincke; Jérome Bertherat; Tim M Strom; Bruno Allolio Journal: N Engl J Med Date: 2014-02-26 Impact factor: 91.245
Authors: Suzan L Carmichael; Gary M Shaw; Chen Ma; Martha M Werler; Sonja A Rasmussen; Edward J Lammer Journal: Am J Obstet Gynecol Date: 2007-12 Impact factor: 8.661
Authors: Gerald Goh; Ute I Scholl; James M Healy; Murim Choi; Manju L Prasad; Carol Nelson-Williams; John W Kunstman; John W Kuntsman; Reju Korah; Anna-Carinna Suttorp; Dimo Dietrich; Matthias Haase; Holger S Willenberg; Peter Stålberg; Per Hellman; Göran Akerström; Peyman Björklund; Tobias Carling; Richard P Lifton Journal: Nat Genet Date: 2014-04-20 Impact factor: 38.330